Sofpironium bromide explained
| Tradename: | Ecclock, Sofdra |
| Dailymedid: | Sofpironium bromide |
| Routes Of Administration: | Topical |
| Atc Prefix: | None |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
| Legal Status: | JP: Rx-only |
| Cas Number: | 1628106-94-4 |
| Pubchem: | 86301316 |
| Chemspiderid: | 52085312 |
| Unii: | 7B2Y1932XU |
| Kegg: | D10989 |
| Chembl: | 3707223 |
| Synonyms: | BBI-4000, BBI 4000 |
| Iupac Name: | [(3''R'')-1-(2-Ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2R)-2-cyclopentyl-2-hydroxy-2-phenylacetate bromide |
| C: | 22 |
| H: | 32 |
| Br: | 1 |
| N: | 1 |
| O: | 5 |
| Smiles: | CCOC(=O)C[N+]1(CC[C@H](C1)OC(=O)[C@@](C2CCCC2)(C3=CC=CC=C3)O)C.[Br-] |
| Stdinchi: | 1S/C22H32NO5.BrH/c1-3-27-20(24)16-23(2)14-13-19(15-23)28-21(25)22(26,18-11-7-8-12-18)17-9-5-4-6-10-17;/h4-6,9-10,18-19,26H,3,7-8,11-16H2,1-2H3;1H/q+1;/p-1/t19-,22+,23?;/m1./s1 |
| Stdinchikey: | FIAFMTCUJCWADZ-JOFREBOKSA-M |
Sofpironium bromide, sold under the brand name Ecclock among others, is a medication used to treat hyperhidrosis (excessive sweating). It is an anticholinergic and is applied to the skin.
It was approved in Japan in 2020, for the treatment of primary axillary hyperhidrosis.[2] [3] It was approved for medical use in the United States in June 2024.[4]
Medical uses
Sofpironium bromide is indicated for the treatment of primary axillary hyperhidrosis.
Mechanism of action
Sofpironium bromide is an anticholinergic agent that reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands.[5] It is a retrometabolically-designed drug (or "soft drug") based on glycopyrronium bromide,[6] [7] meaning it has been designed to exert the desired effects at the site of administration, after which it is quickly converted into an inactive non-toxic metabolite upon entering systemic circulation avoiding the typical anticholinergic side-effects caused by off-site action.
Society and culture
Brand names
Sofpironium bromide is the international nonproprietary name.[8]
It is marketed as Ecclock in Japan and as Sofdra in the US.
External links
Notes and References
- Web site: Sofdra (sofpironium) topical gel, 12.45% . 20 June 2024 . 20 June 2024 . https://web.archive.org/web/20240620233727/https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217347s000lbl.pdf . live .
- Paik J . Sofpironium Bromide: First Approval . Drugs . 80 . 18 . 1981–1986 . December 2020 . 33236266 . 10.1007/s40265-020-01438-1 . 227155835 .
- Gregoriou S, Campanati A, Rigopoulos D, Maria Offidani A, Stratigos A, Kontochristoulos G . Investigational topical anticholinergics in clinical development for the treatment of hyperhidrosis . Expert Opinion on Investigational Drugs . 30 . 5 . 479–482 . May 2021 . 33691553 . 10.1080/13543784.2021.1900114 . 232187568 . free .
- FDA Approves Sofdra topical gel . Botanix Pharmaceuticals . 20 June 2024 . 20 June 2024 . 20 June 2024 . https://web.archive.org/web/20240620230416/https://botanixpharma.com/fda-approves-sofdra-topical-gel/ . live .
- Yokozeki H, Fujimoto T, Abe Y, Igarashi M, Ishikoh A, Omi T, Kanda H, Kitahara H, Kinoshita M, Nakasu I, Hattori N, Horiuchi Y, Maruyama R, Mizutani H, Murakami Y, Watanabe C, Kume A, Hanafusa T, Hamaguchi M, Yoshioka A, Egami Y, Matsuo K, Matsuda T, Akamatsu M, Yorozuya T, Takayama S . A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis . The Journal of Dermatology . 48 . 3 . 279–288 . March 2021 . 33410265 . 7986147 . 10.1111/1346-8138.15668 .
- Huang F, Brown CE, Wu WM, Juhász A, Ji F, Bodor N . Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics . Pharmaceutical Research. 20 . 10 . 1681–9 . October 2003 . 10.1023/a:1026160023030 . 14620526. 20657068 .
- Ji F, Wu W, Dai X, Mori N, Wu J, Buchwald P, Bodor N . Synthesis and pharmacological effects of new, N-substituted soft anticholinergics based on glycopyrrolate . J. Pharm. Pharmacol. . 57 . 11 . 1427–35 . November 2005 . 16259775 . 10.1211/jpp.57.11.0008. free .
- ((World Health Organization)) . 2017 . International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 77 . WHO Drug Information . 31 . 1 . 10665/330984 . free . World Health Organization .
